Health Experts Call For Action Against Dengue, Citing Sanofi Pasteur’s Vaccine

Business Insider: Another worrisome problem is afflicting many of the same places where Zika is spreading
“…There’s a commercial vaccine that’s now available for dengue, but it still isn’t available to everyone who needs it. In December, the company developing it, global pharmaceutical giant Sanofi, got approval to distribute its dengue vaccine in some of the areas that need it the most. Sanofi is also one of many companies hot on the trail of a possible Zika vaccine. Business Insider spoke with Sanofi’s Chief Scientific Officer, Dr. Gary Nabel, about why the road ahead is so challenging…” (Ramsey, 2/25).

Thomson Reuters Foundation: Health experts press for urgent, integrated approach to tackle dengue
“Health experts called on Thursday for urgent action to tackle the ‘global dengue pandemic,’ and said the number of cases was expected to spike in some countries this year, partly because of the El Niño weather phenomenon. … One impetus for the call to action is Sanofi Pasteur’s new Dengvaxia vaccine that has received approval in Mexico, Brazil, El Salvador, and the Philippines, said Dr. In-Kyu Yoon, director of the Dengue Vaccine Initiative (DVI), adding that other vaccines were in the development pipeline…” (Tang, 2/25).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.